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Background: Gonadotropin-releasing hormone (GnRH) stimulation test is the gold standard to identify central precocious puberty 
(CPP). This test requires multiple blood samples at different time points to measure gonadotropin levels, and is therefore expensive, 
time-consuming, and uncomfortable for patients. We aimed to simplify the GnRH stimulation test to require fewer blood samples. 
Methods: A study of 166 girls with precocious puberty was undertaken. Blood samples were obtained at 0, 15, 30, 45, 60, 90, and 
120 min after GnRH administration, and the levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were mea-
sured. For each parameter, the sensitivities and specificities were estimated and ROC curves were constructed.
Results: One hundred and twenty-eight patients (77.1%) were diagnosed for CPP. Peak LH levels were achieved 30 min after GnRH 
stimulation in patients with CPP. Further, 98.4% of the 45-min samples were diagnostic for CPP, and the cumulative frequency of LH 
values of ≥5 IU/L was 100% at 45 min. Using this cut-off value for LH, the ROC curve for LH at 45 min showed the highest sensitivi-
ty (98.4%) and specificity (100%) in the diagnosis of CPP. 
Conclusions: Values of LH measured from a single blood sample obtained at 45 min in the GnRH stimulation test may be adequate 
for the diagnosis of CPP. Two samples, taken at 30 and 45 min after stimulation, were able to accurately diagnose CPP in 100% of 
the patients in this study.
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INTRODUCTION
Precocious puberty is generally defined as the onset of 
secondary sexual characteristics before 8 yr of age in girls 
and 9 yr in boys [1, 2]. Precocious puberty caused by cen-
tral activation of the hypothalamic-pituitary-gonadal (HPG) 
axis is classified as gonadotropin-dependent, also called true 
or central precocious puberty (CPP). Isolated forms of ab-
normal pubertal development, such as premature thelarche 
(PT), are not associated with central activation of the HPG 
axis, and are classified as peripheral precocious puberty [3]. 
CPP occurs at least 10-fold more frequently in girls than in 
boys; in more than 90% of girls, sexual precocity is idiopa-
thic. It is estimated that precocious puberty affects between 
1 in 5,000 and 1 in 10,000 children, and a recent study found 
a much higher incidence of CPP in girls compared with 40 
yr ago [4, 5]. Gonadotropin releasing hormone (GnRH) sti-
mulation test is the gold standard to reveal premature acti-
vation of the HPG axis in patients with precocious puberty 
[6, 7]. 
However, this test needs a clinical investigation unit and 
repeated blood sampling at 5-8 time points to measure the 
levels of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) [8-10]. The duration of the test is 90 to 120 
min and 15 to 25 mL of blood is required. As such, this test 
is comparatively expensive, time-consuming, painful, and 
uncomfortable for patients [9-13]. To avoid these problems, 
several alternatives such as measurement of basal LH and 
FSH values, and the subcutaneous leuprolide acetate test Kim HK, et al.  •  GnRH Test for Precocious Puberty
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with a single sample, have been attempted [14-17]. None of 
these alternative methods have yet been standardized suffi-
ciently or proven equal or superior to GnRH test. 
In this study, we investigated whether the GnRH test to 
diagnose CPP could be simplified without altering its valid-
ity, by estimating the values of LH and FSH at various time 
points after GnRH stimulation.
MATERIALS AND METHODS
1. Subjects
This retrospective study was done by reviewing the medi-
cal records of 166 girls, who presented at our hospital with 
early pubertal signs between July 2009 and December 2010. 
Evaluation included documentation of the history of onset 
and the progression of pubertal changes, including Tanner 
breast and pubic hair stages, height and weight, growth ve-
locity, and GnRH stimulation testing. The indication for the 
GnRH stimulation test was the onset of pubertal signs be-
fore the age of 8 yr in girls. Bone age was evaluated by the 
method of Greulich and Pyle [18]. This study was approved 
by the Institutional Review Board of our hospital.
2. GnRH stimulation test
A standard dose of 100 µg GnRH (Relefact; Sanofi-Aven-
tis, Frankfurt am Main, Germany) was administered as an 
intravenous (IV) bolus. An IV cannula was inserted and 
blood samples were obtained immediately before the injec-
tion and at 15, 30, 45, 60, 90, and 120 min after the injection. 
3. Hormone assays
Serum LH, FSH, and estradiol were measured by direct 
chemiluminescence, using the ADVIA Centaur
® Immuno-
assay System (Siemens Healthcare Diagnostics Inc., Tarry-
town, NY, USA). The detection limits for LH, FSH, and es-
tradiol were 0.07 IU/L, 0.6 IU/L, and 10 pmol/L, respecti-
vely. A stimulated LH value of ≥5 IU/L was considered di-
agnostic for CPP in patients with pubertal signs [19]. Pa-
tients who had a stimulated LH value of <5 IU/L were clas-
sified as having PT. 
4. Analysis
Statistical analyses were performed using the Statistical 
Package for Social Sciences software package for Windows 
(version 19.0; SPSS Inc., Chicago, IL, USA). Values are re-
ported as median, range, and frequency. The Mann-Whit-
ney U test was used to compare medians. A P value of less 
than 0.05 was considered statistically significant. The diag-
nostic values of LH and FSH, as well as the LH/FSH ratio at 
different time points during the GnRH test, were evaluated 
using ROC curve analysis. 
RESULTS
A hundred and sixty-six girls showing signs of early pu-
berty were enrolled in this study. In 128 out of 166 (77.1%) 
tests, the peak LH was above the cut-off value, and the test 
was diagnostic for CPP. The remaining girls (38 out of 166, 
22.9%) had an evoked LH value of <5 IU/L, and were clas-
sified as undergoing PT. The clinical characteristics and hor-
mone levels of both groups are presented in Table 1. Signifi-
cant differences in chronological age and bone age were seen 
between the 2 groups. Basal LH and FSH levels in the group 
with CPP were higher than in the PT group (P<0.001). Eval-
uation of the LH/FSH ratio demonstrated statistically signi-
ficant differences between the CPP and PT groups in both 
the basal and peak states (P<0.001).
Basal and peak LH levels in the CPP group were signifi-
cantly greater than in the PT group (both, P<0.001) (Fig. 1). 
Both LH and FSH levels showed a rapid increase after GnRH 
stimulation in both groups. However, the increase in LH le-
vels was more robust in the CPP group than in the PT group, 
while FSH responses were almost similar in the 2 groups 
(Fig. 2). The peak LH level was achieved 30 min after GnRH 
stimulation in the CPP group, and 45 min after stimulation 
in the PT group, while FSH levels continued to rise throu-
ghout the test in both groups (Fig. 2). The peak LH/FSH ra-
tio was achieved in 15 min after GnRH stimulation in both 
groups (Fig. 2).
Among CPP patients, 98.4% (126 of 128 tests) of the 45-
min samples were diagnostic for CPP, with LH levels of ≥5 
Table 1. Clinical and biochemical parameters of patients with CPP and PT
CPP group (N=128)  PT group (N=38) P value
Chronological age (yr)  8.3 (5.7-8.9)  7.9 (4.9-8.8)  <0.001
Bone age (yr) 10.5 (6.6-12.2)  9.7 (6.9-11.6)  <0.001
Height age (yr)  9.1 (5.6-11.8)  9.0 (6.0-11.5)  0.690
Body weight (kg) 29.5 (17.1-57.1) 29.8 (20.7-51.2)  0.721
Basal LH (IU/L) 0.42 (0.07-4.93)  0.07 (0.07-0.47)  <0.001
Basal FSH (IU/L)  3.14 (0.30-12.01)  2.05 (0.30-6.98)   0.002
Basal LH/FSH ratio  0.14 (0.02-1.41)  0.04 (0.01-0.23)  <0.001
Basal E2 (pmol/L) 12.91 (10.00-92.95) 10.95 (10.00-41.90)   0.120
Peak LH (IU/L) 8.82 (5.02-58.65)   3.07 (0.68-4.95)   <0.001
Peak FSH (IU/L) 16.29 (5.70-37.10)    16.62 (4.89-23.53)  0.748
Peak LH/FSH ratio  0.74 (0.23-5.38)   0.26 (0.11-0.63)  <0.001
Values are presented as median (range).
Abbreviations: CPP, central precocious puberty; PT, premature thelarche; yr, years; LH, 
luteinizing hormone; FSH, follicle-stimulating hormone; E2, estradiol.246     www.kjlm.org
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Fig. 1. Comparison of basal (A) and peak (B) LH concentrations following GnRH stimulation, between CPP patients (N=128) and PT patients (N=38). Box-plots 
show the median, interquartile range, outliers, and extreme cases.
Abbreviations: LH, luteinizing hormone; GnRH, gonadotropin releasing hormone; CPP, central precocious puberty; PT, premature thelarche.
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Fig. 2. Comparison of (A) LH and (B) FSH concentrations, and (C) LH/FSH ra-
tio, versus time after GnRH stimulation, between CPP and PT patients. Data 
are presented as median and 95% CI. 
Abbreviations: LH, luteinizing hormone; FSH, follicle-stimulating hormone; 
GnRH, gonadotropin releasing hormone; CPP, central precocious puberty; PT, 
premature thelarche; CI, confidence intervals. Kim HK, et al.  •  GnRH Test for Precocious Puberty
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IU/L (Table 2). The 2 patients who had stimulated LH levels 
below this cut-off value at 45 min, showed values above the 
cut-off at 30 min. Therefore, the cumulative frequency of 
LH values of ≥5 IU/L at 45 min was 100% (Table 2).
Fig. 3 shows the ROC curves of LH at different time points 
of the test in all patients. The ROC curve for LH at 45 min 
had the greatest area under the curve (AUC) and was hence 
the most effective for diagnosing CPP. 5 IU/L was consid-
ered as the cut-off value for LH in the diagnosis of CPP, and 
the ROC curves indicate that an LH cut-off value of 4.99 
IU/L at 45 min resulted in high sensitivity (98.4%) and spec-
ificity (100%) in the diagnosis of CPP. 
Pubertal development of breast was compatible with Tan-
ner stages 2 and 3 in 89.8% and 10.2% of girls, respectively. 
Pubic hair development was compatible with Tanner stages 
1 and 2 in 95.2% and 4.8% of girls, respectively. 
 DISCUSSION
CPP may have profound physical and psychological ef-
fects on affected children and their families. It is accompa-
nied by growth acceleration, advancement of bone age, and 
elevated sex steroid hormone levels for age. Therefore, early 
menarche and significant impairment of final height can re-
sult in untreated CPP patients. Mogensen et al. [20] report  ed 
a significant increase in the number of CPP patients over 
the recent 16-yr period. This trend also occurred in Korean 
girls with a 4- to 5-fold increment in CPP patients over the 
recent 5-yr period. 
The gold standard for laboratory confirmation of CPP is 
the GnRH stimulation test. However, this test results in sig-
nificant cost, time, and discomfort to the patient, as well as 
a potential delay in diagnosis. Different cut-off levels of peak 
LH are used in the diagnosis of CPP in patients with early 
pubertal signs. Further, cut-off levels differ depending on 
the assays used to measure LH [19, 21, 22]. Previous studies 
have suggested that GnRH-stimulated LH levels between 
30 and 60 min are sufficient to diagnose CPP [21, 23-25]. In 
Korean patients with CPP, Choi et al. [26] tried to simplify 
the standard GnRH stimulation test, suggesting that a single 
LH determination at 30 min was diagnostic. However, their 
study included only 33 patients. We analyzed the LH and 
FSH response to the GnRH test performed to diagnose pre-
cocious puberty in 166 patients. To our best knowledge, the 
current study comprises the largest homogeneous Korean 
population in this regard. 
We measured LH levels by a direct chemiluminescence 
immunoassay, and a cut-off stimulated LH value of ≥5 IU/L 
was considered diagnostic for CPP. In 126 out of 128 (98.4%) 
CPP patients tested, 45-min samples were diagnostic for CPP 
using this cut-off value. The remaining 2 patients, who had 
stimulated LH levels of <5 IU/L at 45 min, had levels above 
the cut-off value at 30 min. Therefore, the cumulative fre-
quency of LH values of ≥5 IU/L at 45 min was 100%. These 
findings indicate that 2 samples, obtained at 30 and 45 min 
after stimulation, can be used in a simplified GnRH test for 
discriminating patients with CPP from patients with PT. 
Neely et al. [14] reported that a basal LH value of >0.1 
IU/L was diagnostic for CPP with 94% sensitivity and 88% 
Table 2. Frequency (%) of LH cut-off value of ≥5 IU/L at each time point during the GnRH stimulation test in CPP patients 
Basal  15 m  30 m  45 m  60 m  90 m  120 m
Cross-sectional frequency of LH ≥5 IU/L  0 (0)  79 (61.7)  119 (92.9)   126 (98.4)  119 (92.9)  93 (72.7)  64 (50.0)
Cumulative frequency of LH ≥5 IU/L 0 (0)  79 (61.7)  119 (92.9)  128 (100)  128 (100)  128 (100)  128 (100)
Abbreviations: LH, luteinizing hormone; GnRH, gonadotropin-releasing hormone; CPP, central precocious puberty; m, minute.
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specificity. They also reported that a cut-off value of >0.3 
IU/L increased the specificity to 100%, although the sensi-
tivity decreased. In our study, the basal LH level in the group 
with CPP was higher than that of the PT group (0.42 and 
0.07 IU/L, respectively, P<0.001). However, analysis of the 
diagnostic value of basal LH using ROC curves revealed low 
sensitivity and specificity of basal LH levels for the diagno-
sis of CPP (data not shown). In addition, we observed that 
29 of the 128 patients (22.7%) diagnosed with CPP by the 
GnRH stimulation test showed undetectable basal LH levels 
(LH <0.07 IU/L). Therefore, an elevated basal LH was highly 
predictive of a positive GnRH test result, whereas a low basal 
LH did not eliminate central pubertal activation. We, there-
fore, do not suggest using basal LH as a single diagnostic mar-
ker for CPP.
The LH/FSH ratio has been considered of value by some 
investigators who reported that CPP in girls is usually ac-
companied by an LH/FSH ratio of >1.0 [8]. However, noc-
turnal LH secretion and the LH response to GnRH may be 
low at early puberty, and the LH/FSH ratio may remain low 
until mid-puberty [22]. Changes in this ratio at puberty are 
predominantly caused by increasing LH levels. In the current 
study, LH/FSH ratio showed significant differences between 
CPP and PT groups in both basal and peak states (P<0.001), 
with the basal and peak LH/FSH ratios being 0.14 and 0.74, 
respectively, in the CPP group. A basal LH/FSH ratio of >0.2 
as a diagnostic tool for CPP had a sensitivity of 36.7% and 
specificity of 97.4%. With an LH/FSH ratio cut-off value of 
>0.5, the diagnostic sensitivities at 15, 30, 45, 60, 90, and 
120 min were 77.3%, 76.6%, 69.5%, 57.8%, 40.1%, and 35.2%, 
respectively, while the specificities were 94.7%, 97.4%, 98.9%, 
100%, 100%, and 100%, respectively. The limited utility of 
the LH/FSH ratio seems to be a consequence of the consid-
erable variation of FSH levels seen in patients. 
Although FSH concentrations were also observed to in-
crease in response to the GnRH stimulation test in this study, 
FSH levels were indistinguishable between the CPP and PT 
groups, and the peak FSH levels of the CPP and PT groups 
had poor diagnostic value (P=0.748). Data from other stu-
dies also indicate that FSH has poor diagnostic value for CPP 
[10, 14, 21]. Therefore, FSH concentrations cannot be used 
in diagnosing CPP, and the accurate measurement of LH 
suffices for diagnostic confirmation of CPP.
In conclusion, a single LH value measured 45 min after 
GnRH stimulation is highly sensitive and specific for the 
diagnosis of CPP, using a cut-off value of ≥5 IU/L. Two sam-
ples, obtained at 30 and 45 min after stimulation, were able 
to accurately diagnose all CPP patients in this study. Alth-
ou  gh further study is required, we suggest that repeated bl-
ood sampling is unnecessary, and that 2 samples obtained 
at 30 and 45 min can be used in a simplified GnRH test to 
evaluate precocious puberty. The proposed simplified test 
will substantially diminish the cost and discomfort to the 
patient. 
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